Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Medical oncologist Dr. Greg Riely, MSKCC, summarizes the development of acquired resistance after a good initial response to EGFR inhibitor therapy and the clinical patterns of progression commonly seen.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Dr. Greg Riely, medical oncologist from MSKCC, considers the evidence on whether there are clinically significant differences among the currently available first and second generation oral EGFR inhibitors for patients with an EGFR mutation.
Medical oncologist Dr. Greg Riely, MSKCC, discusses evidence for whether there are clinically significant differences among specific EGFR mutations that should lead to differences in management.
Firstly, having looked at this forum in the past, I am in awe of the knowledge, courage and empathy of those that use and support it. So to my...
Hi! My 74 year old mom was diagnosed with small cell lung cancer in September 2017 and she has been on chemotherapy since then. The main tumor is...
Myy dad was diagnosed with small cell lung cancer in Aug. 2017. He received the cisplatin/etoposide chemo and 30 days of radiation. He finished...
Husband diagnosed with stage 4 lung cancer, 4 rounds chemo, then tarceva targeted therapy for 14 months. Recently has rapidly experienced mental...
My father has an EGFR exon 20 insertion mutation. We found out today that the PD-L1 was 60% which apparently is rare for an exon 20 insertion, but it...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.